NEWS DESK
Building your stock news briefing…
Biogen Inc. - Common Stock (BIIB) is currently showing a slightly bearish headline tone with a mixed / range backdrop. The latest news flow is being framed here as context rather than prediction, so beginners can quickly see whether headlines are helping, hurting, or complicating the chart story. Earnings tone is currently no clear earnings read.
NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. (“Biogen” or the “Company”) (NASDAQ: BIIB). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Biogen said on Wednesday it would acquire drug discovery company RayThera for $1 billion, including milestone payments.
LOS ANGELES, June 11, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or "the Company") (NASDAQ: BIIB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
This section is separated from the general news feed so investors can quickly connect the latest headlines with the structured earnings report.
Steroid use reduction and disease control: In additional results from the Phase 3 PHOENYCS GO study, dapirolizumab pegol (DZP) plus standard of care was associated with sustained disease control at lower glucocorticoid doses through Week 48 compared with placebo plus standard of care, supporting reduced long-term steroid exposure Reduced flare rates and immune marker improvements: In other findings presented at EULAR 2026, improvements in immunological markers and reduced flare rates were observed, supporting the potential of dapirolizumab pegol to address the complex burden of SLE BRUSSELS, Belgium and CAMBRIDGE, Mass.
BRUSSELS, Belgium and CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (Nasdaq: BIIB) today announced that The Lancet, a world-leading medical journal, has published the full results from the Phase 3 PHOENYCS GO clinical trial evaluating dapirolizumab pegol (DZP), an investigational, novel Fc-free CD40L inhibitor, in patients living with moderate-to-severe active systemic lupus erythematosus (SLE). The results showed statistically significant improvement in disease activity with DZP added to standard of care (SOC) versus placebo plus standard of care.1
Biogen Inc. is currently under investor scrutiny as multiple law firms launch investigations into potential securities law violations, alleging that the company may have issued false or misleading statements or withheld important information. This legal scrutiny is overshadowing recent business moves, including Biogen's announcement of a $1 billion acquisition of RayThera, a drug discovery company. While the acquisition points to strategic growth, the ongoing investigations introduce uncertainty that investors should monitor closely. Biogen's stock is trading in a mixed range with a slightly bearish news sentiment, reflecting cautious market sentiment amid these developments. Traders will likely watch for further updates on the investigations and any impact on Biogen's operations or financial disclosures.
BIIB is not giving a fully clean trend read right now, which makes the quality of follow-through especially important.
Momentum is not especially stretched right now, so price behaviour around fresh headlines may matter more than an extreme oscillator reading.
Last price is $0.00, versus MA50 at — and MA200 at —. Relative to those reference points, BIIB is — vs MA50 and — vs MA200.
NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. (“Biogen” or the “Company”) (NASDAQ: BIIB). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Biogen said on Wednesday it would acquire drug discovery company RayThera for $1 billion, including milestone payments.
LOS ANGELES, June 11, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or "the Company") (NASDAQ: BIIB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.